Werewolf Therapeutics Inc (HOWL)
$6.75
+0.54
(+8.7%)▲
Insights on Werewolf Therapeutics Inc
Decreasing Revenue
Revenue is down for the last 3 quarters, 8.08M → 1.50M (in $), with an average decrease of 50.8% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -5.09M → -12.00M (in $), with an average decrease of 53.7% per quarter
Performance
- $6.10$6.78$6.75
9.63%
Downside
Day's Volatility :10.03%
Upside
0.44%
- $1.57$8.19$6.75
76.74%
Downside
52 Weeks Volatility :80.83%
Upside
17.58%
Returns
| Period | Werewolf Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 42.76% | 0.5% | 0.0% |
6 Months | 168.83% | 11.7% | 0.0% |
1 Year | 168.83% | 6.2% | 2.2% |
3 Years | -61.43% | 13.5% | -23.0% |
Highlights
Market Capitalization | 263.5M |
Book Value | $2.85 |
Earnings Per Share (EPS) | -1.05 |
Wall Street Target Price | 12.5 |
Profit Margin | -187.37% |
Operating Margin TTM | -863.56% |
Return On Assets TTM | -15.11% |
Return On Equity TTM | -31.98% |
Revenue TTM | 19.9M |
Revenue Per Share TTM | 0.56 |
Quarterly Revenue Growth YOY | -79.4% |
Gross Profit TTM | -37.4M |
EBITDA | -38.7M |
Diluted Eps TTM | -1.05 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.32 |
EPS Estimate Next Year | -1.24 |
EPS Estimate Current Quarter | -0.43 |
EPS Estimate Next Quarter | -0.4 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 85.19%
Technicals Summary
Sell
Neutral
Buy
Werewolf Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Werewolf Therapeutics Inc | 2.81% | 168.83% | 168.83% | -61.43% | -61.43% |
 Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
 Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
 Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
 Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Werewolf Therapeutics Inc | 0.66 | NA | NA | -1.32 | -0.32 | -0.15 | NA | 2.85 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Werewolf Therapeutics Inc | Buy | $263.5M | -61.43% | 0.66 | -187.37% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Institutional Holdings
RA Capital Management, LLC
14.38%Mpm Asset Management, LLC
10.02%Adage Capital Partners Gp LLC
7.10%Partner Fund Management LP
5.99%MPM Oncology Impact Management LP
5.59%Bank of America Corp
4.90%
Company Information
we are an immuno-oncology company advancing a pipeline of next generation, transformative cancer treatments.
Organization | Werewolf Therapeutics Inc |
Employees | 47 |
CEO | Dr. Daniel J. Hicklin Ph.D. |
Industry | Services |
